查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607160

胃轻瘫药物市场：依药物类别、适应症、销售管道- 全球预测 2025-2030

Gastroparesis Drugs Market by Drug Class (Anti-Emetic Agents, Botulinum Toxin Injections, Prokinetic Agents), Indication (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis), Sales Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胃轻瘫药物市场价值为43.7亿美元，预计到2024年将达到45.4亿美元，复合年增长率为6.61%，到2030年将达到68.5亿美元。

胃轻瘫药物对于控制与排放延迟相关的症状以及针对对患者生活品质有重大影响的病症极为重要。这些药物的市场包括各种药物解决方案，包括促动力剂、止吐剂和其他旨在缓解噁心、呕吐和胃功能不全的新型製剂。糖尿病和其他导致胃轻瘫的全身性疾病的日益普及推动了对这些药物的需求，从而推动了临床和居家照护环境的需求。应用范围涵盖医院、专科诊所和长期照护机构，最终使用者主要是医疗保健专业人员和有慢性管理需求的患者。影响市场成长的主要因素包括老年人口的扩大、胃轻瘫意识的提高以及药物输送系统的进步。透过专注于个人化医疗方法并利用数位健康技术来提高患者的依从性和治疗效果，可以利用最近的潜在商机。公司可以透过投资创新药物配方的研发以及与医疗保健提供者建立策略伙伴关係来提供全面护理解决方案来利用这些机会。然而，市场面临严格的监管要求、现有药物的潜在副作用以及对有效治疗的高度未满足的需求等挑战。诊断和阐明胃轻瘫的发病机制有其局限性，这使得有效药物的开发更加复杂。创新应优先考虑解决这些差距，包括基因研究和寻找新的治疗靶点，例如Ghrelin促效剂和神经调节方法。产品系列的多样化，包括食品等替代疗法，以及引入用于预测诊断和患者客製化管理的人工智慧，也可能支援业务成长。胃轻瘫药物市场具有巨大的成长潜力，但为了克服其复杂性，需要策略重点关注技术创新和以患者为中心的解决方案，以全面应对当前的挑战。

主要市场统计
基准年[2023] 43.7亿美元
预计年份 [2024] 45.4亿美元
预测年份 [2030] 68.5亿美元
复合年增长率（%） 6.61%

市场动态：快速发展的胃轻瘫药物市场的关键市场洞察

胃轻瘫药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球糖尿病人口不断增加
    • 增加对医疗基础设施的投资，以改善获得医疗服务的机会
  • 市场限制因素
    • 降血脂药物配方原料高成本
  • 市场机会
    • 开发新药的持续研究开发活动
    • 全球监管机构核准的药品核准增加
  • 市场挑战
    • 服用胃轻瘫治疗药物相关的严重副作用

波特五力：驾驭胃轻瘫药物市场的策略工具

波特的五力架构是了解胃轻瘫药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解胃轻瘫药物市场的外部影响

外部宏观环境因素在塑造胃轻瘫药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解胃轻瘫治疗药物市场的竞争状况

对胃轻瘫药物市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵胃轻瘫药物市场供应商的绩效评估

FPNV 定位矩阵是评估胃轻瘫药物市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

制定胃轻瘫药物市场成功之路的策略分析与建议

对于希望加强在全球市场的影响力的公司来说，对胃轻瘫药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球糖尿病患者数量不断增加
      • 增加对医疗基础设施的投资，以改善获得医疗服务的机会
    • 抑制因素
      • 配製降血脂药物所用原料高成本
    • 机会
      • 开发新药的持续研究和开发活动
      • 全球监管机构核准的药品核准增加
    • 任务
      • 服用胃轻瘫治疗药物相关的严重副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的胃轻瘫治疗药物市场

  • 止吐药
  • 肉毒毒素注射
  • 胃肠蠕动促进剂

第七章胃轻瘫治疗药物市场（依适应症）

  • 糖尿病性胃轻瘫
  • 特发性胃轻瘫
  • 术后胃轻瘫

第八章胃轻瘫治疗药物市场：依销售管道

  • 离线
    • 医院药房
    • 零售药房
  • 在线的

第九章北美及南美胃轻瘫治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太胃轻瘫药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东与非洲胃轻瘫药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Atlantic Healthcare PLC
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Cairn Diagnostics
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Medtronic PLC
  • Neurogastrx, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Processa Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.
Product Code: MRR-C002B1C996F5

The Gastroparesis Drugs Market was valued at USD 4.37 billion in 2023, expected to reach USD 4.54 billion in 2024, and is projected to grow at a CAGR of 6.61%, to USD 6.85 billion by 2030.

Gastroparesis drugs are pivotal in managing symptoms associated with delayed gastric emptying, targeting a condition that significantly affects patients' quality of life. The market for these drugs encompasses a range of pharmaceutical solutions, including prokinetics, antiemetics, and other novel formulations aimed at alleviating nausea, vomiting, and gastric motility deficiencies. The necessity for these drugs arises from the increasing prevalence of diabetes and other systemic diseases, which contribute to gastroparesis, driving demand in both clinical and home-care settings. Application scope extends to hospitals, specialty clinics, and long-term care facilities, while end users primarily include healthcare professionals and patients requiring chronic management. Key factors influencing market growth include the expanding geriatric population, heightened awareness about gastroparesis, and advances in drug delivery systems. Recent potential opportunities could be harnessed by focusing on personalized medicine approaches and leveraging digital health technologies to enhance patient adherence and outcomes. Companies can capitalize on these opportunities by investing in R&D for innovative drug formulations and developing strategic partnerships with healthcare providers for integrated care solutions. However, the market faces challenges, such as stringent regulatory requirements, potential side effects of existing drugs, and a high unmet need for effective treatments. Limitations in diagnosis and understanding of gastroparesis etiology further complicate effective drug development. Innovation should prioritize addressing these gaps, such as through genetic research and exploring novel therapeutic targets like ghrelin agonists or neuromodulation methods. Business growth could also be supported by diversifying product portfolios to include alternative treatments like dietary supplements or incorporating artificial intelligence for predictive diagnostics and tailored patient management. While the gastroparesis drug market exhibits substantial growth potential, navigating its complexities requires a strategic focus on both technological innovation and patient-centered solutions to address current challenges comprehensively.

KEY MARKET STATISTICS
Base Year [2023] USD 4.37 billion
Estimated Year [2024] USD 4.54 billion
Forecast Year [2030] USD 6.85 billion
CAGR (%) 6.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastroparesis Drugs Market

The Gastroparesis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in diabetic population across the globe
    • Rising investment in healthcare infrastructure to enhance healthcare accessibility
  • Market Restraints
    • High cost of raw materials used in formulation of hyperlipidemia drugs
  • Market Opportunities
    • Continuous research & development activities for new drug development
    • Increasing drug approvals by the regulatory authorities worldwide
  • Market Challenges
    • Severe side effects associated with the consumption of gastroparesis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Gastroparesis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastroparesis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastroparesis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastroparesis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastroparesis Drugs Market

A detailed market share analysis in the Gastroparesis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastroparesis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastroparesis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastroparesis Drugs Market

A strategic analysis of the Gastroparesis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastroparesis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Atlantic Healthcare PLC, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Cairn Diagnostics, Evoke Pharma, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kyowa Kirin International plc, Lupin Limited, Medtronic PLC, Neurogastrx, Inc., Novartis AG, Pfizer, Inc., Processa Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, Vanda Pharmaceuticals Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Gastroparesis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-Emetic Agents, Botulinum Toxin Injections, and Prokinetic Agents.
  • Based on Indication, market is studied across Diabetic Gastroparesis, Idiopathic Gastroparesis, and Post-surgical Gastroparesis.
  • Based on Sales Channel, market is studied across Offline and Online. The Offline is further studied across Hospitals Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in diabetic population across the globe
      • 5.1.1.2. Rising investment in healthcare infrastructure to enhance healthcare accessibility
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of raw materials used in formulation of hyperlipidemia drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous research & development activities for new drug development
      • 5.1.3.2. Increasing drug approvals by the regulatory authorities worldwide
    • 5.1.4. Challenges
      • 5.1.4.1. Severe side effects associated with the consumption of gastroparesis drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gastroparesis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Emetic Agents
  • 6.3. Botulinum Toxin Injections
  • 6.4. Prokinetic Agents

7. Gastroparesis Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Diabetic Gastroparesis
  • 7.3. Idiopathic Gastroparesis
  • 7.4. Post-surgical Gastroparesis

8. Gastroparesis Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospitals Pharmacies
    • 8.2.2. Retail Pharmacies
  • 8.3. Online

9. Americas Gastroparesis Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gastroparesis Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gastroparesis Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. ANI Pharmaceuticals, Inc.
  • 5. AstraZeneca PLC
  • 6. Atlantic Healthcare PLC
  • 7. Bausch Health Companies Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. Cadila Pharmaceuticals Limited
  • 10. Cairn Diagnostics
  • 11. Evoke Pharma, Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Johnson & Johnson Services, Inc.
  • 14. Kyowa Kirin International plc
  • 15. Lupin Limited
  • 16. Medtronic PLC
  • 17. Neurogastrx, Inc.
  • 18. Novartis AG
  • 19. Pfizer, Inc.
  • 20. Processa Pharmaceuticals, Inc.
  • 21. Sanofi S.A.
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Theravance Biopharma
  • 24. Vanda Pharmaceuticals Inc.
  • 25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GASTROPARESIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTROPARESIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GASTROPARESIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ANTI-EMETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BOTULINUM TOXIN INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PROKINETIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DIABETIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY IDIOPATHIC GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY POST-SURGICAL GASTROPARESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 189. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023